Nasdaq ardx.

Dec 4, 2023 · Ardelyx has generated ($0.12) earnings per share over the last year ( ($0.12) diluted earnings per share). Earnings for Ardelyx are expected to grow in the coming year, from ($0.31) to ($0.24) per share. Ardelyx has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 7th, 2024 ... Ardelyx. 03 Jun, 2022, 08:00 ET. WALTHAM, Mass., June 3, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX ), a biopharmaceutical company founded with a mission to discover, develop and ...Ardelyx, Inc. Common Stock (ARDX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Sean Pavone/iStock via Getty Images. At a Glance. Navigating through robust quarterly sales, particularly from its flagship IBS-C product Ibsrela (tenapanor), Ardelyx (NASDAQ:ARDX) continues to ...26 thg 11, 2023 ... The average one-year price target for Ardelyx (NASDAQ:ARDX) has been revised to 9.84 / share. This is an increase of 6.30% from the prior ...

Home ARDX • NASDAQ Ardelyx Inc Follow Share $4.37 Pre-market: $4.33 (0.92%) -0.040 Closed: Nov 30, 4:01:46 AM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Aurinia Pharmaceuticals Inc...

The forecasts range from a low of 6.06 to a high of $12.60. The average price target represents an increase of 81.50% from its latest reported closing price of 4.73. leaderboard of companies with ...

A high-level overview of Ardelyx, Inc. (ARDX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Free Trial NASDAQ:ARDX Ardelyx (ARDX) Earnings Date, Estimates & Call Transcripts $4.31 -0.01 (-0.23%) (As of 04:25 PM ET) Compare Today's Range $4.20 …Like Altisource, Ardelyx (NASDAQ:ARDX) is another stock that has performed very well during a time that has been tough for stocks overall.Shares in this pharma firm are up more than fourfold over ...Dec 29, 2022 · WALTHAM, Mass., Dec. 29, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that the Office of New Drugs (OND), Center for Drug Evaluation and Research of the U ...

On March 02, Ardelyx ( NASDAQ: ARDX ), now nearly a $800 million cap biopharmaceutical company reported 2022 financial results and provided a business update. Since the initial coverage, shares ...

Sarepta Therapeutics, Inc. Common Stock (DE) (SRPT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Ardelyx Inc (NASDAQ:ARDX) trade information. Instantly ARDX has showed a red trend with a performance of -1.60% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.49 on Monday, 11/27/23 increased the stock’s daily price by 4.01%.Nov 29, 2023 · See the latest Ardelyx Inc stock price (ARDX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. A total of 14 hedge funds in Insider Monkey’s database of hedge funds had stakes in Ardelyx Inc. (NASDAQ:ARDX). The most significant stake in Ardelyx Inc. (NASDAQ:ARDX) was owned by. 6.WALTHAM, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Dec 3, 2023 · Ardelyx (NASDAQ:ARDX – Get Free Report)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a report released on Friday, Benzinga reports. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. Wedbush’s price objective would suggest a potential upside of 89.08% from the company’s previous close. Several other ... Aug 17, 2023 · Ardelyx, Inc. (NASDAQ:ARDX) has gained about 353% over the past 12 months. As of the end of the first quarter of 2023, 20 hedge funds tracked by Insider Monkey were long Ardelyx, Inc. (NASDAQ:ARDX ... The put contract at the $4.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $4.00, but will also ...

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that Nasdaq has halted trading of the Company's common stock.Ardelyx, Inc. Common Stock (ARDX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.14. The biopharmaceutical company earned $56.39 million during the quarter, compared to analysts' expectations of $22.09 million. Ardelyx, Inc. Common Stock (ARDX). Nasdaq Listed ...Dec 1, 2023 · Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved XPHOZAH ...

Here's what investors need to know. Shares of Ardelyx ( ARDX 7.44%) were up 9.5% as of 3:47 p.m. after the biotech company announced better-than-expected third-quarter 2023 results. Ardelyx's ...

Ardelyx (NASDAQ: ARDX) is a biotechnology company that focuses on developing novel therapies for unmet medical needs. The company’s growth and potential breakthroughs in medical treatments could ...Stock analysis for Ardelyx Inc (ARDX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Ardelyx (NASDAQ:ARDX – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research report issued on Friday, Benzinga reports. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. Wedbush’s target price points to a potential upside of 89.08% from the stock’s current price. A number of […]FREMONT, Calif. and WALTHAM, Mass., July 29, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that it has …WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...22 thg 11, 2023 ... Ardelyx (NASDAQ:ARDX) delivers shareholders splendid 109% return over 1 year, surging 15% in the last week alone · Unless you borrow money to ...Ardelyx Inc (NASDAQ:ARDX) Real-Time Quotes. 4.55. BATS BZX Real-Time Price. As of 10:35am ET. +0.19 / +4.36%. Today’s Change. 1.67. From discovery through commercialization, all of us at Ardelyx ® are driven to advance patient care with targeted, first-in-class, novel mechanism therapies that address significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to create targeted, first ...

Nov 6, 2023 · WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

Nov 28, 2023 · Ardelyx Inc (NASDAQ:ARDX) trade information. Instantly ARDX has showed a red trend with a performance of -1.60% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.49 on Monday, 11/27/23 increased the stock’s daily price by 4.01%.

Ardelyx, Inc. (NASDAQ:NASDAQ:ARDX) Q3 2023 Earnings Conference Call October 31, 2023 8:00 AM ETCompany ParticipantsCaitlin Lowie - Vice President of... Oct 31, 2023 seekingalpha.comXPeng Inc. American depositary shares, each representing two Class A ordinary shares (XPEV) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global ...Ardelyx (NASDAQ:ARDX – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research report issued on Friday, Benzinga reports. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. Wedbush’s target price points to a potential upside of 89.08% from the stock’s current price. A number of […]Nov 24, 2023 · Ardelyx Inc (NASDAQ:ARDX) trade information. After registering a -0.23% downside in the last session, Ardelyx Inc (ARDX) has traded red over the past five days. The stock hit a weekly high of 4.49 this Wednesday, 11/22/23, dropping -0.23% in its intraday price action. The 5-day price performance for the stock is 11.37%, and 14.02% over 30 days. Q1 net loss was $26.8 million, but Ardelyx raised $51.9 million through sales of their common stock at an average price of about $3.35, leaving $130.4 million in total cash and investments as of ...Ardelyx, Inc. Common Stock (ARDX) Stock Price, Quote, News & History | Nasdaq MY QUOTES: ARDX Edit my quotes Ardelyx, Inc. Common Stock (ARDX) 0 Add to Watchlist Add to Portfolio Quotes...Analysts have provided the following ratings for Ardelyx (NASDAQ:ARDX) within the last quarter: According to 5 analyst offering 12-month price targets in the last 3 months, Ardelyx has an average ...WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Oct 9, 2023 · According to Seeking Alpha data, Ardelyx's market cap of $864.92M shows decent market confidence, especially with its robust revenue growth forecasts: 2023 at $100.6M, and 2024 at $175.84M ...

On March 3, 2023, Wedbush upgraded their outlook for Ardelyx (NASDAQ:ARDX) from Neutral to Outperform.. Analyst Price Forecast Suggests 47.30% Upside. As of March 4, 2023, the average one-year ...One thing we could say about the analysts on Ardelyx, Inc. (NASDAQ:ARDX) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the ...Force Index charts of Daily price volume action, Weekly price volume action, Monthly price volume action of Ardelyx, Inc. ARDX NASDAQ. Data to use: Daily ...Ardelyx, Inc. (NASDAQ:ARDX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts.Consensus estimates suggest investors ...Instagram:https://instagram. otcmkts fxcofcwbfxex dividend date vzgold company stocks Analysts have provided the following ratings for Ardelyx (NASDAQ:ARDX) within the last quarter: According to 5 analyst offering 12-month price targets in the last 3 months, Ardelyx has an average ... fda approval stockgood health insurance tn WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ... sotstar Find the latest dividend history for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com. ARDELYX INC ( ARDX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 100% based on the firm’s underlying fundamentals and the stock’s ...NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ...